title: [Transplantation of haploidentical hematopoietic stem cells from family members without in vitro T-cell depletion for treatment of hematologic malignancies in pediatric patients].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of haploidentical (from family member donors) hematopoietic stem cell transplantation (HSCT) for children with hematologic malignancies.
  
  
  METHODS
  Fifty-eight children under fourteen years with hematological malignancies underwent haploidentical HSCT. All patients had poor-risk clinical or cytogenetic features and reclassified into high-risk and standard-risk groups. Transplantation outcomes were analyzed.
  
  
  RESULTS
  Of fifty-eight patient/donor pairs, seven (12.1%) were mismatched in two HLA loci, twenty (34.5%) in three loci, and thirty-one (53.4%) in four loci. Follow-ups were performed for a median of 1,663 (752-2,664) days after transplantation. All patients achieved stable engraftments. The cumulative incidence of acute graft-versus-host disease (GVHD) of grades 2-4 was (54.8+/-7.6)%, and that of grades 3-4 was (11.4+/-4.8)%. The cumulative incidence of chronic GVHD was (45.6+/-7.8)% for the total and (19.6+/-6.5)% for the extensive. Thirty-eight patients survived with a 2-year actual overall rate of survival 59.0% and 78.9% in the high-risk and standard-risk group, respectively. The 3-year probability of LFS was (58.6+/-8.0)% and (68.4+/-10.7)%, respectively.
  
  
  CONCLUSIONS
  The results encourage extending haploidentical HSCT without T-cell depletion treatments to children with an indication for transplantation.
authors.affiliation: Peking University People's Hospital; Institute of Hematology, Peking University, Beijing 100044, China.
authors.forename: Daihong
authors.initials: D
authors.lastname: Liu
authors.forename: Kai-yan
authors.initials: KY
authors.lastname: Liu
authors.forename: Lan-ping
authors.initials: LP
authors.lastname: Xu
authors.forename: Huan
authors.initials: H
authors.lastname: Chen
authors.forename: Yu-hong
authors.initials: YH
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Yu
authors.initials: Y
authors.lastname: Wang
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Zhang
authors.forename: Qian
authors.initials: Q
authors.lastname: Jiang
authors.forename: Xiao Jun
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005190:Family; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D006239:Haplotypes; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D008297:Male; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome